231 Users Online
Clostridium Difficile Immunoassays Market Segmented By Test Type such as Toxins A and B (EIA), Common antigen (common enzyme or GDH) Test, Toxigenic Anaerobic Culture Test, Tissue Cytotoxin Neutralization Assay
Clostridium Difficile Immunoassays are specialized testing assay used in the detection of presence of Clostridium Difficile in the stool sample. The Clostridium Difficile Immunoassays is also used in defining bacterial and viral colonies for measure in treatments and evaluation. An approximately 310000 new cases of Clostridium Difficile are screened in the US per year. Additionally the Clostridium Difficile is the major reason of antibiotic related diarrhea.
Causing a prolong stomach associated conditions. The utilization of rapid test kits in the Clostridium Difficile Immunoassays is facilitating the diagnostic time and treatment seeking rate. Primarily most of the Clostridium Difficile infection are induced with pseudomembranous colitis where the associated use of antibiotic is form vulnerability to the normal flora of the body.
The high rate of hospitalization and prolong stays in the hospital is one of the major contributor for the high rate of Clostridium Difficile Immunoassays.
The major driving factor for Clostridium Difficile Immunoassays market is continuously increasing incidences of hospital visits, owning to increasing susceptibility to the infections and higher. Adoption of antibiotic for the infection treatment is anticipated to fuel the demand for the Clostridium Difficile Immunoassays market.
As per data from center for disease control and prevention (CDC) nearly 15000 death are directly associated with the Clostridium Difficile infection in US alone marking as one of the substantial cause of the deaths in United States. The higher mortality is anticipated to fuel the demand for the Clostridium Difficile Immunoassays and aid in the growth of the Clostridium Difficile Immunoassays market.
The category of the fluoroquinolones are highly susceptible for the causing the degradation in the stomach and intestinal permeability. The higher demand for toxin B screening is anticipated to offer lucrative growth opportunity in the Clostridium Difficile Immunoassays market. However, low attrition rate Clostridium Difficile Immunoassays is projected to restrain the growth of the Clostridium Difficile Immunoassays Market.
Geographically, global Clostridium Difficile Immunoassays market is segmented into seven key regions viz. North America, Latin America, Europe, East Asia, South Asia, Oceania and Middle East & Africa. North America leads the overall Clostridium Difficile Immunoassays Market.
Advancement in drug designing and availability of higher antibiotics, higher adoption to junk foods, increase awareness about antibiotic associated conditions, increase in hospital acquired infection awareness and favorable regulatory policies have improved the regulatory scenario for global Clostridium Difficile Immunoassays market in North America.
Additionally in East Asia region considerably higher market growth rate is expected due to constant growth in immunoassay market. Transversely affecting the Clostridium Difficile Immunoassays market.
Some of the major key players competing in the global Clostridium Difficile Immunoassays Market are Hologic Inc., TECHLAB, Inc. Roche AG, Merck & Co., Pfizer, Inc., Actelion Pharmaceuticals, Thermo Fisher Scientific Inc., Alere, Inc., Trinity Biotech, Baxter International Inc., Sanofi S.A., Summit Therapeutics, AstraZeneca Plc., and Novartis AG among others.